Skip to content

The comparison of intravenous dexamethasone and paracetamol in the prevention of post Dural puncture headache in elective cesarean section under spinal anesthesia

The comparison of intravenous dexamethasone and paracetamol in the prevention of post Dural puncture headache in elective cesarean section under spinal anesthesia

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20141009019470N80
Enrollment
290
Registered
2019-06-09
Start date
2019-06-20
Completion date
Unknown
Last updated
2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cesarean. Newborn (suspected to be) affected by Cesarean delivery

Interventions

Intervention 1: Interventional group: patients in the first group receive 8 mg dexamethasone in 100 cc normal saline via micro set and three way in 15 minutes. Intervention 2: Intervention group:Pati

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: ASA I-II Minimum NPO time = 8 hours Elective cesarean section

Exclusion criteria

Exclusion criteria: Spinal anesthesia Contraindications of Local infection in the lumbar region (spinal cord needle entry site) Use anti-platelet and anticoagulant Sensitivity to Local anesthesia Diabetes mellitus kidney Diseases Renal failure Coagulation disorder Liver disease Heart disease History of seizure or any neurological disease Migraine and pressure headaches The history of drug addiction Failure of spinal anesthesia or multiple attempts to perform spinal anesthesia more than once Systolic blood pressure above 150 and less than 100 Preeclampsia IUGR The lack of proper growth of the uterus Weight above 100 Height less than 150 and more than 180 cm Hemoglobin less than 8 Caesarean section more than 3 times Sensitivity to dexamethasone and paracetamol

Design outcomes

Primary

MeasureTime frame
Headache. Timepoint: At the arrival to the recovery room and after discharge from the recovery room at 6,12,24,48,72 hr. Method of measurement: Visual Analog Score.

Secondary

MeasureTime frame
Incidence of Nausea and Vomiting. Timepoint: At the arrival to the recovery room and after discharge from the recovery room at 6,12,24,48,72 hr. Method of measurement: Observasion.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Hosein Pourjafarian

Shiraz University of Medical Sciences

mhpj57@gmail.com+98 71 3647 4270

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026